Patient demographic, clinical and treatment characteristics
| Total | Adalimumab | Golimumab | ||
| N=183 | N=96 | N=87 | P value | |
| Age at treatment initiation (years) | ||||
| N | 183 | 96 | 87 | 0.2971 |
| Mean (SD) | 45.6 (15.0) | 44.4 (15.6) | 46.8 (14.3) | |
| Median | 45.3 | 42.7 | 47.1 | |
| Sex, n (%) | ||||
| N | 183 | 96 | 87 | 0.0026 |
| Female | 74 (40.4) | 49 (51.0) | 25 (28.7) | |
| Male | 109 (59.6) | 47 (49.0) | 62 (71.3) | |
| BMI (kg/m2) | ||||
| N | 55 | 17 | 38 | 0.7936 |
| Mean (SD) | 26.95 (5.79) | 26.64 (5.95) | 27.09 (5.79) | |
| Median | 25.83 | 25.51 | 26.41 | |
| Charlson Comorbidity Index | ||||
| N | 183 | 96 | 87 | 0.0503 |
| Mean (SD) | 0.10 (0.42) | 0.16 (0.55) | 0.03 (0.18) | |
| Median | 0.00 | 0.00 | 0.00 | |
| Disease extent at diagnosis, n (%) | ||||
| N | 183 | 96 | 87 | 0.3384 |
| Ulcerative proctitis | 26 (14.2) | 11 (11.5) | 15 (17.2) | |
| Proctosigmoiditis | 12 (6.6) | 9 (9.4) | 3 (3.4) | |
| Left-sided colitis | 54 (29.5) | 26 (27.1) | 28 (32.2) | |
| Pancolitis | 59 (32.2) | 31 (32.3) | 28 (32.2) | |
| Do not know | 32 (17.5) | 19 (19.8) | 13 (14.9) | |
| Time between UC diagnosis and treatment initiation (months) | ||||
| N | 168 | 84 | 84 | 0.3974 |
| Mean (SD) | 95.4 (107.6) | 88.3 (114.0) | 102.4 (101.0) | |
| Median | 58.1 | 43.9 | 63.7 | |
| Treatment line, n (%) | ||||
| N | 183 | 96 | 87 | 0.7129 |
| First-line biologic | 146 (79.8) | 78 (81.3) | 68 (78.2) | |
| Second-line biologic | 37 (20.2) | 18 (18.8) | 19 (21.8) | |
| First-line biologic for patients at second line, n (%) | ||||
| N | 37 | 18 | 19 | 0.4022 |
| Adalimumab | 1 (2.7) | 0 (0.0) | 1 (5.3) | |
| Golimumab | 1 (2.7) | 1 (5.6) | 0 (0.0) | |
| Infliximab (bio-originator) | 19 (51.4) | 10 (55.6) | 9 (47.4) | |
| Infliximab (biosimilar) | 14 (37.8) | 7 (38.9) | 7 (36.8) | |
| Other | 2 (5.4) | 0 (0.0) | 2 (10.5) | |
| Antidrug antibodies after first-line biologic, n (%) | ||||
| N | 37 | 18 | 19 | 0.4501 |
| Positive | 9 (24.3) | 6 (33.3) | 3 (15.8) | |
| Negative | 10 (27.0) | 4 (22.2) | 6 (31.6) | |
| Not known/not tested | 18 (48.6) | 8 (44.4) | 10 (52.6) | |
BMI, body mass index; IQR, inter-quartile range; SD, standard deviation; UC, ulcerative colitis.